Analysts pick Pacific Edge to double in value Jarden initiates coverage with a bullish outlook. - NBR
Printable View
Analysts pick Pacific Edge to double in value Jarden initiates coverage with a bullish outlook. - NBR
You are welcome, Longhaul!
Phenomenal growth in telehealth in the Medicare arena
From the CMS
“During the COVID-19 pandemic, actions by the Trump Administrationhave unleashed an explosion in telehealth innovation, and we’re now moving tomake many of these changes permanent,” said HHS Secretary Alex Azar. “Medicarebeneficiaries will now be able to receive dozens of new services viatelehealth, and we’ll keep exploring ways to deliver Americans access tohealthcare in the setting that they and their doctor decide makes sense forthem.”
“Telehealth has long been a priority for the Trump Administration,which is why we started paying for short virtual visits in rural areas longbefore the pandemic struck,” said CMS Administrator Seema Verma. “But thepandemic accentuated just how transformative it could be, and several monthsin, it’s clear that the healthcare system has adapted seamlessly to a historic telehealthexpansion that inaugurates a new era in healthcare delivery.”
Finalizing Telehealth Expansion and ImprovingRural Health
Before the COVID-19 public health emergency (PHE), only 15,000fee-for-service beneficiaries each week received a Medicare telemedicineservice. Since the beginning of the PHE, CMS has added 144 telehealth servicessuch as emergency department visits, initial inpatient and nursing facilityvisits, and discharge day management services, that are covered by Medicarethrough the end of the PHE. These services were added to allow for safe accessto important health care services during the PHE. As a result, preliminary datashow that between mid-March and mid-October 2020, over 24.5 million out of 63million beneficiaries and enrollees have received a Medicare telemedicineservice during the PHE.
The growth appears to be from 15000 to 875000 per week using a 28 week time frame
What was the forecasted date on that article for it double in value?
Jarden's 12-month target price is $1.40. The valuation was based on a 10-year discounted cash flow analysis. (They are estimating ~1m tests in the final year of the DCF forecast.)
Their analysts estimate the company will remain loss-making until March 2023 when it would potentially make a net profit of $17m from revenue of $57m. They estimate revenue of $900m in the year to March 2030.
Important to note that funds managed by Jarden subsidiary, Harbour Asset Management, hold 14.5% of PEB so there's a vested interest in this outcome.
Nice to see analysts taking an interest at last though.
And even if PEB gets only halfway up the hill towards $1.40 in the next 12 months there will be some happy holders - including moi.
Bonne chance to all holders.
DISCL: PEB is currently 17% of my portfolio - looks like it could get quite a bit higher!
Merci for posting Pierre.
At 75c the Mcap is $544M, so to wait 3 yrs to get to a miserable $17M profit on todays price, never mind double, doesn't look exciting.
Whats happened to fundamentals these days, have they gone mental?
2030, now thats tastier, but a long way away.
It's enough to weaken a bloke's bladder
Merci Beaucoup Pierre, was the Jarden analysis based on Current Commercial Arrangements that PEB has signed thus far?